scholarly journals Identification of six serum antigens and autoantibodies for the detection of early stage epithelial ovarian carcinoma by bioinformatics analysis and liquid chip analysis

2018 ◽  
Author(s):  
Yupeng Zou ◽  
Li Li
Keyword(s):  
Ovarian Carcinoma ◽  
Bioinformatics Analysis ◽  
Early Stage ◽  
Epithelial Ovarian Carcinoma ◽  
Chip Analysis ◽  
Serum Antigens

Twenty years treating early-stage epithelial ovarian carcinoma patients with adjuvant platinum-based chemotherapy. A single institution’s experience

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 5167-5167 ◽  
Author(s):  
J. A. García-Saénz ◽  
A. Casado ◽  
J. Puente ◽  
S. López-Tarruella ◽  
J. C. Camara ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Early Stage ◽  
Epithelial Ovarian Carcinoma ◽  
Platinum Based Chemotherapy

Clinically Apparent Early Stage Invasive Epithelial Ovarian Carcinoma: Should All Be Treated Similarly?

1999 ◽  
Vol 74 (2) ◽  
pp. 252-254 ◽  
Author(s):  
T. Le ◽  
G.V. Krepart ◽  
R.J. Lotocki ◽  
M.S. Heywood
Keyword(s):  
Ovarian Carcinoma ◽  
Early Stage ◽  
Epithelial Ovarian Carcinoma

scholarly journals The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis

2021 ◽  
Author(s):  
Renée E.W.M. van de Vorst ◽  
Jacob P. Hoogendam ◽  
Maaike A. van der Aa ◽  
Petronella O. Witteveen ◽  
Ronald P. Zweemer ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ovarian Carcinoma ◽  
Early Stage ◽  
Meta Analysis ◽  
Epithelial Ovarian Carcinoma ◽  
Surgical Staging

scholarly journals Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma

2019 ◽  
Vol 16 (4) ◽  
pp. 637 ◽  
Author(s):  
Shu-Feng Hsieh ◽  
Hei-Yu Lau ◽  
Hua-Hsi Wu ◽  
Heng-Cheng Hsu ◽  
Nae-Fang Twu ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Cox Regression ◽  
Clear Cell ◽  
Early Stage ◽  
Disease Free Survival ◽  
Tumor Grade ◽  
Epithelial Ovarian Carcinoma ◽  
Gynecology And Obstetrics

We aimed to determine prognostic factors of early stage (I/II) epithelial ovarian carcinoma (EOC) including clinicopathologic and chemotherapeutic regimens. Four hundred and thirty-seven women who underwent primary staging surgery with adjuvant chemotherapy between January 1, 2000 and December 31, 2010 were retrospectively reviewed and analyzed from two medical centers. The prognostic factors were determined from multivariate survival analyses using Cox regression models. The majority of women were diagnosed with stage Ic (244/437, 55.8%). The histopathologic types were clear cell (37.5%), endometrioid (27.2%), serous (14.0%), and mucinous (13.3%). Fifty-seven percent (249/437) of the women received taxane-based (platinum plus paclitaxel) regimens and 43.0% received non-taxane (platinum plus cyclophosphamide) regimens as frontline adjuvant chemotherapy. Clear cell tumors (adjusted Hazard ratio (aHR) 0.37, 95% confidence interval (CI) 0.21–0.73, p = 0.001) showed better 5-year disease-free survival (DFS) than serous tumors. Women diagnosed at FIGO (International Federation of Gynecology and Obstetrics) stage II (aHR 5.97, 95% CI = 2.47–14.39, p < 0.001), grade 3 tumor without clear cell (aHR 2.28, 95% CI = 1.02–5.07, p = 0.004) and who received 3–5 cycles of non-taxane regimens (aHR 3.29, 95% CI = 1.47–7.34, p = 0.004) had worse 5-year overall survival (OS). Clear cell histology treated with taxane-based regimens showed significantly higher 5-year DFS (91.2% vs. 82.0%, aHR = 0.45, 95% CI = 0.21–0.93, p = 0.043) and 5-year OS (93.5% vs. 79.0%, aHR = 0.30, 95% CI = 0.13–0.70, p = 0.005) than those treated with non-taxane-based regimens. We conclude that stage, tumor grade, and chemotherapeutic regimens/cycles are independent prognostic factors for early stage ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document